6.48
Valneva Se Adr stock is traded at $6.48, with a volume of 371.55K.
It is up +0.93% in the last 24 hours and down -43.21% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$6.42
Open:
$6.66
24h Volume:
371.55K
Relative Volume:
8.45
Market Cap:
$562.96M
Revenue:
$197.44M
Net Income/Loss:
$-114.14M
P/E Ratio:
-4.7265
EPS:
-1.371
Net Cash Flow:
$-40.20M
1W Performance:
-42.09%
1M Performance:
-43.21%
6M Performance:
-34.87%
1Y Performance:
-8.35%
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
VALN
Valneva Se Adr
|
6.48 | 557.75M | 197.44M | -114.14M | -40.20M | -1.371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - FinancialContent
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study - Yahoo Finance
VALN Shares Plunge Following Uncertain Outcomes in Lyme Disease Vaccine Trial - Bitget
Jefferies reiterates Valneva stock Buy rating after Lyme trial data - Investing.com
Valneva (NASDAQ:VALN) Sees Large Volume IncreaseHere's Why - MarketBeat
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive - Benzinga
HC Wainwright Has Positive Forecast for Valneva Q3 Earnings - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why - Defense World
FY2030 Earnings Forecast for Valneva Issued By HC Wainwright - Defense World
Valneva (NASDAQ:VALN) Shares Gap DownHere's What Happened - MarketBeat
FY2030 Earnings Estimate for Valneva Issued By HC Wainwright - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap UpStill a Buy? - MarketBeat
Earnings call transcript: Valneva SE Q4 2025 sees EPS beat, stock rises - Investing.com Canada
[20-F] Valneva SE Files Annual R... | VALN SEC FilingForm 20-F - Stock Titan
Valneva SE earnings beat by $0.13, revenue topped estimates - Investing.com India
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
Valneva (NASDAQ:VALN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Valneva (NASDAQ:VALN) Trading Up 7.1%Here's What Happened - MarketBeat
Valneva (NASDAQ:VALN) Stock Price Down 5.6%Here's What Happened - MarketBeat
Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. By Investing.com - Investing.com Nigeria
Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. - Investing.com
Wise and Virbac Benefit from Quarterly Results, Valneva and Logitech Slide - marketscreener.com
VLA Stock Price and Chart — EURONEXT:VLA - TradingView — Track All Markets
Valneva (NASDAQ:VALN) Shares Up 4.9%What's Next? - MarketBeat
Valneva (NASDAQ:VALN) Stock Price Down 4.6%Time to Sell? - MarketBeat
Valneva (NASDAQ:VALN) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Valneva SE Sponsored ADR $VALN - MarketBeat
Valneva stock rises after positive final Phase 2 results for chikungunya vaccine - Investing.com India
Valneva (NASDAQ:VALN) Stock Price Down 3.1%What's Next? - MarketBeat
Valneva stock rises after positive Lyme disease vaccine booster data - Investing.com
Valneva SE earnings beat by $0.02, revenue fell short of estimates - Investing.com
Valneva (VALN) Projected to Post Earnings on Thursday - MarketBeat
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - 2822news.com
Free cash flow per share of Valneva SE Sponsored ADR – LS:A3CPD1 - TradingView
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):